Takeda maintains annual guidance despite first-quarter profit drop
Reuters
Published Jul 28, 2022 02:44AM ET
Updated Jul 28, 2022 07:21AM ET
TOKYO (Reuters) -Japan's biggest drugmaker Takeda Pharmaceutical Co reported a sharp drop in first-quarter profit on Thursday, reflecting one-off gains a year earlier, while maintaining annual earnings forecasts that are buoyed by the yen's decline.
Operating profit for April-June totalled 150.5 billion yen ($1.11 billion), the company said, compared with 249 billion yen a year earlier.
The company kept its forecast for full-year operating profit at 520 billion yen, up 13% from the previous period. That compares with a consensus forecast of 539 billion yen, according to a Refinitiv poll of 15 analysts.
In the first quarter of last fiscal year, Takeda benefited from a one-time gain of 131.4 billion yen when it sold off its diabetes assets to refocus on core businesses following its acquisition of Shire Plc (LON:SHP).
The next major driver for Takeda's earnings and shares may be a decision by European regulators, expected later this year, on the company's experimental vaccine for Dengue fever.
The company has been a key player in Japan's COVID-19 vaccine strategy. It imported vaccines made by Moderna (NASDAQ:MRNA) Inc and is domestically producing the shots developed by Novavax (NASDAQ:NVAX) Inc, approved by Japanese regulators in April.
The Shire acquisition, completed in January 2019, expanded Takeda's drug pipeline and diversified its global sales, with about half now coming from the United States. Those U.S. earnings are now worth more when brought back to Japan, where the yen has depreciated to a 24-year low.
"If we apply the June-end FX rates to the rest of fiscal year 2022, for example 136 yen to the U.S. dollar, we would expect to see over 10 percentage points of incremental growth to our forecasts," Chief Financial Officer Costa Saroukos told analysts.
($1=135.3400 yen)
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.